Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
Abstract Number: 1765 • ACR Convergence 2022
Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
Ana Pons¹, José Rosas¹, José Miguel Senabre², JC Cortés-Quiroz¹, Carmen Raya-Santos², Gregorio Santos-Soler², Lara Pons², Marisa Lorente², José Antonio Bernal³, Xavier Barber⁴ and José Alberto Garciía-Gómez⁴, ¹Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain, ²Hospital Marina Baixa, Villajoyosa, Spain, ³Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁴CIO Miguel Hernández University Elche, Alicante, Spain
Background/Purpose: Patients receiving treatment with JAK inhibitor drugs (JAKi) have an increased risk of developing herpes zoster (HZ). A new recombinant vaccine effective against HZ…
Abstract Number: 1956 • ACR Convergence 2022
Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study
Sarah J.H. Khidir¹, Bastiaan van Dijk², Marloes Verstappen¹, Elise van Mulligen³ and Annette van der Helm-van Mil⁴, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Erasmus Medical Center, Leiden University Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: In the pre-arthritis phase of Rheumatoid Arthritis (RA), symptoms resulting in physical disabilities already occur. It is unknown whether functional disabilities start in hands…
Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Daniela Grimaldi¹, Kathryn Reid¹, Phyllis Zee¹, Rowland Chang⁴ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Evanston, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…
Abstract Number: 1991 • ACR Convergence 2022
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
Siba Raychaudhuri¹, Smriti Raychaudhuri² and Heike Wulff³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²VA Medical Center, Sacramento, CA, ³UC Davis, Davis, CA
Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1.…
Abstract Number: 2007 • ACR Convergence 2022
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
Yoshihiko Hoshida¹, Atsuko Tsujii², Shiro Ohshima², Yukihiko Saeki², Masato Yagita³, Tomoya Miyamura⁴, Masao Katayama⁵, Yasushi Hiramatsu⁶, Hisaji Oshima⁷, Toshihiko Murayama⁸, Shinji Higa⁹, Fuminori Hirano¹⁰, Kenji Ichikawa¹¹, Noriyuki Chiba¹², Takao Sugiyama¹³, Atsushi Ihata¹⁴, Akiko Mitsuo¹⁵, Hiroshi Tsutani¹⁶, Koichiro Takahi¹⁷, Akira Okamoto¹⁸, Shigeru Yoshizawa¹⁹, Yasuo Suenaga²⁰, Shunsuke Mori²¹, Shoichi Nagakura²², Norie Yoshikawa²³, Atsuhisa Ueda²⁴, Shouhei Nagaoka²⁵, Keigo Setoguchi²⁶, Shoji Sugii²⁷, Asami Abe²⁸, Toshiaki Sugaya²⁹, Masahiro Koseto³⁰, Yasuo Kunugiza³¹, Norishige Iizuka³², Ryosuke Yoshihara³³, Tomoaki Fujisaki³⁴, Hiroyuki Sugahara³⁵, Ikuo Saito³⁶, Kazuya Kuraoka³⁷, Norihiro Teramoto³⁸, Masahiro Ito³⁹, Kenichi Taguchi⁴⁰, Yuko Minami⁴¹, Shinji Naito⁴², Mitsuharu Nomoto⁴³, Kazuyoshi Saito⁴⁴, Kiyoshi Matsui⁴⁵, Yasuhiko Tomita⁴⁶, Hiroshi Furukawa⁴⁷ and Shigeto Tohma⁴⁸, ¹Department of Pathology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ²Department of Rheumatology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ³Division of Inflammation and Immunity, Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Osaka, Japan, ⁴Department of Rheumatology, NHO Kyushu Medical Center, Fukuoka, Japan, ⁵Department of Rheumatology, NHO Nagoya Medical Center, Nagoya, Japan, ⁶Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁷National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ⁸Department of Pathology, NHO Kumamoto Medical Center, Kumamoto, Kumamoto, Japan, ⁹Division of Rheumatology, Daini Osaka Police Hospital, Osaka, Osaka, Japan, ¹⁰Department of Rheumatology, NHO Asahikawa Medical Center, Asahikawa, Hokkaido, Japan, ¹¹Department of Rheumatology, NHO Hokkaido Medical Center, Sapporo, Japan, ¹²epartment of Rheumatology, NHO Morioka Medical Center, Morioka, Japan, ¹³Department of Rheumatology, NHO Shimoshizu Hospital, SIkaido, Chiba, Japan, ¹⁴Department of Rheumatology, NHO Yokohama Medical Center, Yokohama, Japan, ¹⁵Department of Rheumatology, NHO Disaster Medical Center, Tachikawa, Japan, ¹⁶Department of Rheumatology, NHO Awara Hospital, Awara, Fukui, Japan, ¹⁷Department of Rheumatology, NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ¹⁸Department of Rheumatology, NHO Himeji Medical Center, Himeji, Japan, ¹⁹Department of Rheumatology, NHO Fukuoka Hospital, Fukuoka, Japan, ²⁰Department of Rheumatology, NHO Beppu Medical Center, Beppu, Oita, Japan, ²¹Department of Rheumatology, NHO Kumamoto Saishun Medical Center, Goshi, Japan, ²²Department of Hematology, NHO Kumamoto Minami Hospital, Ushiro, Japan, ²³Department of Rheumatology, NHO Miyakonojo Medical Center, Miyakonojo, Japan, ²⁴Department of Rheumatology, Yokohama City University, Yokohama, Japan, ²⁵Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²⁶Department of Systemic immunological diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, ²⁷Department of Internal Medicine, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ²⁸Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²⁹Department of Rheumatology, Fuchu Hospital, Izumi, Japan, ³⁰Department of Laboratory Medicine and Internal Medicine (Clinical Immunology), Nippon Life Hospital, Osaka, Osaka, Japan, ³¹Department of Orthopedics, JCHO Hoshigaoka Medical Center, Hirakata, Japan, ³²Department of Pathology, Kishiwada City Hospital, Kishiwada, Japan, ³³Department of Rheumatology, Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ³⁴Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan, ³⁵Department of Hematology, Sumitomo Hospital, Osaka, Osaka, Japan, ³⁶Department of Pathology, NHO Sagamihara Hospital, Sagamihara, Kanagawa, Japan, ³⁷Department of Diagnostic Pathology, NHO Kure Medical Center /Chugoku Cancer Center, Kure, Hiroshima, Japan, ³⁸Department of Pathology, NHO Shikoku Cancer Center, Matsuyama, Japan, ³⁹Department of Pathology, NHO Nagasaki Medical Center, Nagasaki, Japan, ⁴⁰Department of Pathology, NHO Kyushu Cancer Center, Fukuoka, Japan, ⁴¹Department of Pathology, NHO Ibarakihigashi Hospital, Nakagun, Japan, ⁴²Department of Pathology, NHO Ureshino Medical Center, Ureshino, Japan, ⁴³Department of Pathology, NHO, Kagoshima Medical Center, Kagoshima, Japan, ⁴⁴First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴⁵Hyogo College of Medicine, Nishinomiya, Japan, ⁴⁶Department of Pathology, International University of Health and Welfare, Narita, Japan, ⁴⁷Department of Rheumatology, NHO Tokyo National Hospital, Tokyo, Japan, ⁴⁸National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: The effect of antirheumatic drugs on the development of lymphoproliferative disorders (LPDs) in rheumatoid arthritis (RA) patients remains unclear. The current study aimed to…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
Abstract Number: 2252 • ACR Convergence 2022
Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Joshua Baker³, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…
Abstract Number: 0129 • ACR Convergence 2022
Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Marinella Govoni¹, Anastas Batalov², Dimitrios Boumpas³, Salvatore D'Angelo⁴, Filip De Keyser⁵, Rene-Marc Flipo⁶, Herbert Kellner⁷, Hermine Leroi⁸ and Ahmed Khalifa⁹, ¹MSD Italy, Cento, Italy, ²Medical University of Plovdiv, Plovdiv, Bulgaria, ³National and Kapodistrian University of Athens, Heraklion, Greece, ⁴Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ⁵Department of Rheumatology, Ghent University Hospital, Maldegem, Belgium, ⁶CHU Lille, Boulogne-Billancourt, France, ⁷Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁸MSD Belgium, Woluwe-Saint-Lambert, Belgium, ⁹MSD Sharp & Dohme GmbH, Germany, Kriens, Switzerland
Background/Purpose: Patients with inflammatory arthritis often experience secondary non-response to a first-line tumor necrosis factor alpha inhibitor (TNFαi). GO-BEYOND is a study program comprised of…
Abstract Number: 0244 • ACR Convergence 2022
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
Yicong Li¹, Chun Wu², Michael Maldonado², Peter Schafer², S. Louis Bridges, Jr.³, William Rigby⁴, Vivian Bykerk³, Jane Buckner⁵ and Jinqi Liu², ¹Parexel International, Durham, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Hospital for Special Surgery, New York, NY, ⁴Dartmouth Hitchcock Medical Center, Lebanon, PA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…
Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
You-Jung Ha¹, Seunghwan Shin², SE RIM CHOI³, Eun Ha Kang¹ and Yun Jong Lee¹, ¹Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Lunit Inc, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…
Abstract Number: 0277 • ACR Convergence 2022
Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
Xavier Mariette¹, Sandrine Aspeslagh², Richard Moriggl³, Vijay Rajendran⁴, Christine Rudolph⁵, Paul Van Hoek⁵, Nadia Verbruggen⁵, Christopher Watson⁶, Sven Borchmann⁷ and Andreas Stallmach⁸, ¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²UZ Brussel, Brussels, Belgium, ³University of Veterinary Medicine, Vienna, Austria, ⁴Galapagos NV, Gent, Belgium, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁷Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, ⁸Department of Internal Medicine IV, Jena University Hospital, Jena, Germany
Background/Purpose: Filgotinib (FIL) is a preferential oral Janus kinase (JAK) 1 inhibitor, approved for the treatment of RA and ulcerative colitis (UC) in Europe, the…
Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Roy Fleischmann¹, Sebastian Meerwein², Christina Charles-Schoeman³, BERNARD COMBE⁴, Stephen Hall⁵, Nasser Khan⁶, Kyle Carter⁷, Heidi Camp⁸ and Andrea Rubbert-Roth⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁴Montpellier University, Montpellier, France, ⁵Emeritus Research and Monash University, Melbourne, Australia, ⁶AbbVie, Inc., Abbott Park, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Abbvie, Winnetka, IL, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…
Abstract Number: 0312 • ACR Convergence 2022
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Lara Pupim¹, Gerd Burmester², Fang Fang¹, Alan Kivitz³, Moses Njenga¹, Costantino Pitzalis⁴, Jay Chatfield¹, Anastassia Papandrikopoulou¹, Manoj Samant¹, Steve Schmitz¹, Madeline Spiers¹, Eben Tessari¹, John Ziemniak¹ and John F. Paolini⁵, ¹Kiniksa, Lexington, MA, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Queen Mary University of London, London, United Kingdom, ⁵Kiniksa Pharmaceuticals, Lexington, MA
Background/Purpose: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKi-IR). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].